Kyle Mikson

Stock Analyst at Canaccord Genuity

(0)
# 4872
Out of 5,240 analysts
78
Total ratings
14.89%
Success rate
-28.35%
Average return
22 Stocks
Name Action Price Target Current % Upside Ratings Updated
Exagen
Maintains: Strong Buy
5 7
3 133.33% 2 Jan 3, 2025
Natera
Maintains: Strong Buy
165 180
169.09 6.45% 6 Jan 3, 2025
Repligen
Initiates Coverage On: Hold
165
158 4.43% 1 Dec 17, 2024
Akoya Biosciences
Maintains: Buy
6 4
2.72 28.68% 3 Nov 15, 2024
Lucid Diagnostics
Maintains: Buy
3 3
0.82 265.85% 4 Nov 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
2 1
2.38 -57.98% 3 Nov 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
95 75
55.63 34.82% 9 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
130 145
138.78 4.48% 6 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
35 42
25.95 61.85% 3 Oct 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
32 20
16.09 24.3% 6 Oct 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
4 3
1.94 54.64% 7 Aug 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
3 5
0.29 1624.14% 3 Jul 30, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
30 38
38.75 -1.94% 4 Jun 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
32 25
8.67 188.35% 4 Apr 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
26
n/a n/a 2 Mar 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
4
1.15 204.35% 2 Mar 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
5 2
n/a n/a 4 Nov 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
3
n/a n/a 4 Sep 25, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
3 2
0.66 203.03% 2 Aug 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
50
0.6 8100% 1 Mar 30, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
19
1.99 854.77% 1 Jan 29, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
150
0.55 27172.73% 1 Jan 29, 2021